Inovio Biomedical Corp secures Korean approvalÂ to beginÂ clinical trials for SynCon universal flu vaccine

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Research and Markets: The Report 'PV Innovation in North America'...
Research and Markets: Vietnam Telecommunications Services Market Report:...
Research and Markets: Indonesia Soft Drinks Review 2011: consumption,...
Northampton family thank Red Cross with generous donation to county...
Research and Markets: Malaysia Soft Drinks Review 2011: consumption,...
Simon Ward - The MPC is making another policy...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Inovio Biomedical Corp secures Korean approvalÂ to beginÂ clinical trials for SynCon universal flu vaccine
DNA vaccines developer Inovio Biomedical Corp (NYSE Amex:INO) declared on Tuesday that its affiliate VGX International Inc (Korea:011000) has received approval in Korea to start a Phase I clinical trial for Inovio's SynCon preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza....

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search